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ABSTRACT
Objective To report the clinical and investigative
features of children with a clinical diagnosis of probable
autoimmune encephalopathy, both with and without
antibodies to central nervous system antigens.
Method Patients with encephalopathy plus one or
more of neuropsychiatric symptoms, seizures, movement
disorder or cognitive dysfunction, were identiﬁed from
111 paediatric serum samples referred from ﬁve tertiary
paediatric neurology centres to Oxford for antibody
testing in 2007–2010. A blinded clinical review panel
identiﬁed 48 patients with a diagnosis of probable
autoimmune encephalitis whose features are described.
All samples were tested/retested for antibodies to N-
methyl-D-aspartate receptor (NMDAR), VGKC-complex,
LGI1, CASPR2 and contactin-2, GlyR, D1R, D2R,
AMPAR, GABA(B)R and glutamic acid decarboxylase.
Results Seizures (83%), behavioural change (63%),
confusion (50%), movement disorder (38%) and
hallucinations (25%) were common. 52% required
intensive care support for seizure control or profound
encephalopathy. An acute infective organism (15%) or
abnormal cerebrospinal ﬂuid (32%), EEG (70%) or MRI
(37%) abnormalities were found. One 14-year-old girl
had an ovarian teratoma. Serum antibodies were
detected in 21/48 (44%) patients: NMDAR 13/48
(27%), VGKC-complex 7/48(15%) and GlyR 1/48(2%).
Antibody negative patients shared similar clinical
features to those who had speciﬁc antibodies detected.
18/34 patients (52%) who received immunotherapy
made a complete recovery compared to 4/14 (28%)
who were not treated; reductions in modiﬁed Rankin
Scale for children scores were more common following
immunotherapies. Antibody status did not appear to
inﬂuence the treatment effect.
Conclusions Our study outlines the common clinical
and paraclinical features of children and adolescents
with probable autoimmune encephalopathies.
These patients, irrespective of positivity for the
known antibody targets, appeared to beneﬁt from
immunotherapies and further antibody targets may
be deﬁned in the future.
INTRODUCTION
Encephalopathy in children and adolescents is asso-
ciated with a high rate of morbidity and mortality
and poses difﬁcult diagnostic and therapeutic chal-
lenges.1 2 The differential diagnoses are diverse,
including infectious, para-infectious, metabolic,
genetic, traumatic, malignant and toxic disorders.1 3
The clinical features of these disorders overlap and,
in many cases, the cause will not be apparent from
the history and examination at presentation.
Clinical observation, investigation and treatment
often need to be carried out simultaneously.1
Antibody-mediated encephalopathies, in which
patients present with neurological syndromes asso-
ciated with serum and/or cerebrospinal ﬂuid (CSF)
antibodies directed against ion channels, receptors
and associated proteins, are now well recognised in
adults.4–6 Although the antigenic targets are gener-
ally expressed throughout the nervous system, the
clinical picture can localise to speciﬁc areas of the
central nervous system (CNS). Many patients
present with amnesia, confusion, seizures and psy-
chiatric features,4 and some then develop a more
generalised encephalopathy with a movement dis-
order.5 In some patients the encephalopathy can be
part of a paraneoplastic neurological disorder; the
presence of a tumour depends not only on the type
of autoimmune disorder, but also on the age and
gender. Nevertheless, the majority of patients do
not have detectable tumours.4
Autoimmune encephalopathies are increasingly
being diagnosed in children with antibodies to
N-methyl-D-aspartate receptor (NMDAR),7–10 and
in some with antibodies to voltage-gated potassium
channel (VGKC)-complex proteins11–17 or other
CNS antigens such as glutamic acid decarboxylase
(GAD).14 In a large US cohort,7 40% of NMDAR
antibody encephalitis presented in childhood or
adolescence, and in a smaller study from the UK,
23% of patients were under the age of 18.8
Additionally, in a multicentre UK encephalitis
study,18 16/75 (21%) of patients without a detected
infection were found retrospectively to have a
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speciﬁc antibody, a frequency that was higher than any individ-
ual virus identiﬁed. A similar observation regarding NMDAR
antibodies was made in the Californian encephalitis project.19
The clinical phenotypes associated with these conditions are
increasingly recognised but some patients are negative for the
available antibody tests. In order to assess the clinical and inves-
tigative features, immunotherapy responses and outcomes, in
patients with speciﬁc antibodies, and to compare them with
those in whom no antibodies were detected, we studied patients
whose sera were referred from ﬁve paediatric neurology centres,
and selected for study those in whom the ﬁnal diagnosis was of
a probable autoimmune encephalopathy.
METHODS
Patient selection and review of immunotherapy response
The children, all under 18 years, were seen at the Evelina
Children’s Hospital, London (n=36), Great Ormond Street
Children’s Hospital, London (n=30), Birmingham Children’s
Hospital, Birmingham (n=28), St George’s Hospital, London
(n=10) and King’s College Hospital, London (n=7) between
2007 and 2010. Serum samples from these 111 patients were
sent to the Oxford laboratory for testing for CNS autoanti-
bodies. These children underwent extensive diagnostic studies as
indicated by the clinical history to exclude infective, genetic and
metabolic disorders. Clinical data, comprising demographic
information, clinical features at presentation, discharge and
follow-up, and results of laboratory, electrophysiological and
neuroimaging testing, were compiled (YH and SW), and pre-
sented anonymously, and without revealing available antibody
positivity, to a multicentre review panel of four paediatric neu-
rologists (AC, CH, EW, ML). Patients were considered to have a
probable immune-mediated encephalopathy if they presented
with encephalopathy (depressed or altered level of conscious-
ness, lasting more than 24 h, lethargy, or change in personality
or behaviour) as previously deﬁned,18 and at least one of the
following features: neuropsychiatric symptoms, seizures, move-
ment disorder, or cognitive dysfunction. Patients were excluded
if an alternative diagnosis was made but included even if the
diagnosis of probable autoimmune encephalopathy was made
retrospectively. In addition, we chose to exclude patients with
demyelinating disease (who are being studied separately) and
two with Rasmussen encephalitis, as well as those whose
encephalopathy was given an alternative diagnosis (see ﬁgure 1
for details). An immunotherapy response was deﬁned as ‘deﬁn-
ite’ if the response could not be attributed to another factor or
when patients were treatment-dependent and relapsed on dis-
continuation. A ‘probable’ response was when a confounder
such as antiepileptic drugs or possible spontaneous
Figure 1 Study ﬂow chart showing
expert review and record linkage
outcome. Four patients who were
excluded from the study because they
were not encephalopathic were
positive for autoantibodies in the
serum; two had VGKC-complex
antibodies (one Guillain–Barré
syndrome and one myositis) and two
had N-methyl-D-aspartate receptor
antibodies (one movement disorder,
one optic neuritis). Patients with
demyelinating conditions, Rasmussen
encephalitis, or with neurological
symptoms secondary to systemic
diseases could have an autoimmune
mechanism for their disorder but were
excluded from this study.
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improvement could not be excluded. The outcomes, as mea-
sured by the range of difﬁculties the patients were experiencing
(cognitive, behaviour, seizure and motor), were retrieved from
the patient’s medical records or, if unavailable, were obtained
directly from the patient’s primary paediatric neurologist. Full
recovery was deﬁned by the absence of medical, educational and
social concerns reported from parents, school and the patient’s
primary clinician at follow-up (minimum follow-up time of
1 year). We also applied the modiﬁed Rankin Scale (mRS) for
children, as previously used by Bigi et al,20 to assess the degree
of disability both during the acute admission and at follow-up.
Ethical approval for this study was from the Oxfordshire
Regional Ethical Committee A (07/Q1604/28).
Autoantibody testing
All samples were tested originally for VGKC-complex or
NMDAR antibodies as requested. Retrieved sera, and the four
CSFs sent, were retested for all available antibodies. Serum (at
1:20 dilution) antibodies to NMDAR, leucine-rich glioma inac-
tivated 1 (LGI1), contactin-associated protein 2 (CASPR2;
serum at 1:100), contactin-2, glycine receptor (GlyR), and the
dopamine receptors 1 and 2 (D1R and D2R) were tested using
cell-based assays in routine clinical use. D1R and D2R full-
length human dopamine receptors were individually subcloned
from image clones into the mammalian expression vector
pcDNA-DEST40. Monoclonal antibodies (anti-D1 dopamine
receptor produced in rat, Sigma-Aldrich D2944; anti-DRD2
antibody produced in mouse, WH0001813M1 SIGMA), con-
ﬁrmed good surface expression of the antigens. For all the cell-
based assays, the binding of serum IgG to the surface of human
embryonic kidney cells, transfected with cDNA encoding the
auto-antigen, is visualised using a ﬂuorescence-labelled second-
ary antibody. The binding is scored visually on a range from 0
(negative) to 4 (very strong) as in previous studies.8 21 22 AMPA
receptor (AMPAR) and GABA(B)R antibodies were tested using
a commercial assay (Euroimmun, Luebeck, Germany) and nega-
tivity conﬁrmed with in-house tests. VGKC-complex antibodies
were measured by immunoprecipitation of rabbit brain
VGKC-complexes labelled with radioactive dendrotoxin
(normal <100 pM, low positive 100–150 pM, positive 150–
400 pM and high positive >400 pM).23 GAD antibodies were
measured by immunoprecipitation of 125I-recombinant GAD.24
Data analysis
Descriptive statistics were used to summarise the key compo-
nents of patient data. Fisher’s exact test (two-tailed) was used
for comparison of clinical details and investigatory ﬁndings in
the different groups. The χ2 test was used to assess the relation-
ship between clinical improvement and use of immunotherapies.
Data were analysed using GraphPad Prism 5.
RESULTS
Clinical features of the patients and relationship
to autoantibodies
Following the multicentre expert review panel, 48/111 patients
were considered to have a diagnosis of probable autoimmune
encephalopathy (see ﬁgure 1). Of the 48 patients, 26 were
female (mean 8.7 years, range 1.83–17) and 22 were male
(mean 9 years, range 0.16–16). The ages of onset and patients’
demographics are shown in ﬁgure 2. Non-Caucasians were
common, representing 24/48 (50%) of the cohort.
Prodromal symptoms, with either fever and/or associated
infectious episodes, were noted in 27 patients (56%). Three
patients had a recent vaccination (Pandemrix for H1N1, HPV
and Men C booster; 1 month, 4 weeks and 1 week prior to
onset, respectively). The most common presenting features
included seizures (83%; generalised seizures 71%, focal seizures
56%), behavioural changes (63%) and confusion (50%).
Twenty-seven patients had neuropsychiatric symptoms (56%;
agitation 38%, hallucinations 25%) and 18 developed a move-
ment disorder (38%; choreoathetosis 29%, myoclonus 2%,
startle 4%, tremor 4%). Twenty-ﬁve patients (52%) required
intensive care admission for seizure control or reduction in con-
scious level.
Forty-ﬁve patients had NMDAR antibodies requested and 32
patients had VGKC-complex requested initially; positive results
were conﬁrmed on retesting. Overall, 21 patients were antibody
positive; 13 patients (27%, mean age 8.9, range 1.83–17) were
positive for NMDAR antibodies, with cell-based assay scores of
2.5–4 (controls <1); one of the two CSFs was also positive.
Sera from seven different patients (17%, mean age 9, range
4–15) immunoprecipitated VGKC-complexes, with results
ranging from 105 to 1360 pM; the only CSF available for
testing was negative for these antibodies. Two of the
VGKC-complex antibody patients were also positive for GAD
antibodies, one of them with type 1 diabetes mellitus, but none
were positive for LGI1, CASPR2 or contactin-2 antibodies.
A 5-year-old girl who presented with explosive-onset epileptic
encephalopathy (without rigidity and myoclonus) was found to
have GlyR antibodies in her serum (score 2.5) and CSF (score
1). None of the patients had antibodies to AMPAR, GABA(B)R
(conﬁrmed subsequently with in-house assays), D1R or D2R.
Table 1 demonstrates no apparent differences in clinical features
between the antibody positive and negative groups. However,
Figure 2 Demographics of patients
with autoimmune encephalopathy.
(A) Age at disease onset of the 48
paediatric patients with autoimmune
encephalopathy divided between
antibody positive and antibody
negative, male and female patients.
(B) Ethnicity of the 48 paediatric
patients with autoimmune
encephalopathy; 24 patients (50%)
were non-Caucasian: Asian (13),
Black (5) and Other (6).
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when the clinical features of patients with NMDAR antibodies
and VGKC-complex antibodies were compared, there was a
trend towards more frequent movement disorders and hallucina-
tions with the NMDAR antibodies (table 2).
CSF analysis, neuroimaging and electrophysiological studies
CSF analysis revealed lymphocytosis in 8/47 (17%) patients and
oligoclonal bands in 6/47 (13%, table 3). Interestingly, three
patients had organisms identiﬁed in the CSF (two herpes
simplex virus (HSV), one adenovirus); the two positive for HSV
became progressively worse despite adequate antiviral therapy
and were found to have NMDAR antibodies when
reinvestigated.
Brain imaging was normal in 35/48 (73%) at presentation and
the remaining patients had increased T2 changes in the cortex
(n=6), hippocampus (n=3), white matter (n=3) or basal ganglia
(n=1). These changes had normalised by 3 months but ﬁve
patients developed atrophy on a repeat scan (table 3). Reversible
MRI changes, without atrophy, were common in the
VGKC-complex antibody patients. By contrast, the majority of
the NMDAR antibody group had a normal MRI at the onset of
the disease, but 4/13 developed atrophy by 6 months (table 2).
One 14-year-old girl, who was positive for NMDAR antibodies,
had an ovarian teratoma identiﬁed by ultrasound.
EEG, at presentation, demonstrated slow background consist-
ent with an encephalopathy in 33/47 (70%) patients. In 10
others, the EEG demonstrated epileptiform discharges early in
the disease course; seven of these progressed to an encephalo-
pathic pattern. In two patients there was slowing of alpha and
increased beta activity, probably due to benzodiazepine use.
Response to immunotherapy in patients with autoimmune
encephalitis
Immunotherapy was given in 34/48 (73%). First-line immuno-
therapies (corticosteroids, intravenous immunoglobulins (IVIG)
and plasma exchange (PLEX)) were given in 29 patients, and
ﬁve required regular immunosuppressive treatment (azathiopr-
ine, cyclophosphamide, rituximab, mycophenolate). Two
patients received immunotherapy late in the disease (more than
6 months from the onset of symptoms) and did not respond to
treatment.
Of the patients who did not receive immunotherapy, only 4/
14 (29%) recovered completely compared to 18/34 (53%) who
received immunotherapy, although this difference did not reach
statistical signiﬁcance. Both HSV/NMDAR antibody positive
children showed a deﬁnite response to intensive immunotherapy
with steroids, IVIG and PLEX. Overall 32/34 (94%) showed
some response to immunotherapy; 23/34 (68%) ‘probably’
responded (7 NMDAR, 3 VGKC-complex, 13 seronegative),
with only 9/34 (28%) showing a ‘deﬁnite’ response (5 NMDAR,
1 VGKC-complex, 3 seronegative) (see earlier deﬁnitions), but
there was no apparent difference in treatment responses
between the antibody positive and the antibody negative groups
(table 4).
Medium term outcome of patients
At the latest follow-up (12–60 months from onset, mean
24 months), 20/48 (42%) patients have made a complete recov-
ery, 24 (50%) still have cognitive and behavioural problems, and
16 (33%) have ongoing seizures with one child still severely dis-
abled (ﬁgure 3). The outcomes in the antibody positive group
have been slightly worse, with only 6/21 (29%) compared to
14/27(52%) in the antibody negative group making a complete
recovery. Nevertheless, the mRS for children scores demon-
strated a signiﬁcant change between nadir and ﬁnal follow-up in
the group as a whole, with trends in both the antibody positive
and negative groups (table 4 and ﬁgure 4).
DISCUSSION
Autoimmune forms of encephalopathies are now well recog-
nised in children as well as adults, but there are few comparative
studies of their clinical and investigative features or outcomes,
and it is not clear what proportions of patients have antibodies
to the CNS targets that have only been identiﬁed in the last few
years. In a group of patients with probable diagnosis of
Table 1 Comparison of the clinical features and association with
infections in paediatric patients with antibody positive and antibody
negative encephalopathy
Antibody positive
(n=21)
Antibody negative
(n=27)
Cognitive dysfunction 18 (86%) 19 (70%)
Behavioural change 16 14
Confusion 11 13
Aphasia 7 7
Amnesia 1 2
Psychiatric disturbances 13 (62%) 14 (52%)
Hallucinations 9 3
Agitation 7 11
Mood disorders 2 1
Obsessive behaviour 0 1
Seizures 18 (86%) 22 (81%)
Generalised 14 20
Focal 15 12
Movement disorders 7 (33%) 11 (41%)
Choreoathetosis 7 (limb 7, face 4) 7 (limb 6, face 2)
Myoclonus 0 1
Startle 0 2
Tremor 0 2
Sleep disorders with disturbed
sleep wake cycle
7 (33%) 11 (41%)
Dysautonomia 2 (1%) 4 (7%)
Blood pressure instability 2 1
Tachycardia/bradycardia 2 3
Fever at presentation 8 (38%) 9 (33%)
Associated infection 10 (47%) 17 (63%)
Mycoplasma 2 2
ASOT 3 3
HSV 2 (PCR positive in
CSF)*
0
EBV 1 0
HHV6 0 1
Influenza 0 3 (2 H1N1, 1
influenza A)
Adenovirus 0 1 (positive in CSF)
Neoplasm 1 (5%) 0 (0%)
Screening for neoplasm 18 (86%) 9 (33%)
No significant difference was seen in cognitive dysfunction, seizures, movement
disorder, dysautonomia, sleep disorders, psychiatric features and associated
infections, immunotherapy response and outcome. The presence of co-existing or
preceding known infective pathogens was identified in both groups. Screening for
neoplasms was done less frequently in the antibody negative group and might reflect
clinicians’ views on the link between autoimmune encephalopathies and malignancies
in patients without a known antigen.
*Both positive for NMDAR-Ab.
ASOT, anti-streptococcal antibody titre; CSF, cerebrospinal fluid; EBV, Epstein–Barr
virus; HHV-6, human herpes virus 6; HSV, herpes simplex virus; NMDAR,
N-methyl-D-aspartate receptor.
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autoimmune encephalopathy, deﬁned by their clinical features
and exclusion of other known causes, we found that 21 (46%)
had antibodies to either the NMDAR (27%, one with an
ovarian teratoma) or the VGKC-complex (17%), and one (2%)
to GlyR antibodies. No signiﬁcant clinical differences were
found between the antibody positive and negative groups.
Moreover, both antibody positive and negative patients
responded to immunotherapies with improvements in the mRS
scores and complete recovery in 20/48 (42%) overall. Thus it
appears that the lack of identiﬁcation of a known antibody by
current available methods should not exclude the diagnosis of
autoimmune encephalopathy, and immunotherapy could be con-
sidered. Future investigations of the antibody negative group
may lead to the deﬁnition of new antigenic targets.
The clinical presentation of patients with NMDAR antibodies
(table 2) is consistent with those previously described in the
Table 2 Comparison of clinical and investigatory findings of patients with VGKC-complex and NMDAR encephalitis
NMDAR, this study
(n=13)
NMDAR antibody encephalitis
(n=32)10
VGKC-complex, this
study (n=7)
VGKC-complex encephalopathy
in children (n=20)*
Age at onset (years) 9.6 (range 1.83–17) 14 (range 1.9–18) 8.9 (range 6–15) 8 (range 0.8–17)
Cognitive dysfunction 13 (100%) 28/32 (88%) Behavioural and personality change 4 (57%) 14 (70%)
Psychiatric problems 10 (77%) N/A 3 (43%) 9 (45%)
Seizures 10 (77%) 23/30 (77%) 7 (100% 12 (60%)
Movement disorders 7 (54%) 26/31 (84%) 0 (0%) 7 (35%)
Fever at presentation 4 (30%) 48% prodrome noted 4 (57%) 8 (50%)
Neoplasm 1(8%) 8 (25%) 0 (0%) 1 (1%)
EEG abnormalities 12 (92%) 25/25 (100%) 7 (100%) 9/9 (100%)
MRI abnormalities (early) 2 (15%) 10/31(32%) 4 (57%) 9 (45%)
MRI abnormalities (late) 4 (31%) N/A 1 (14%) N/A
CSF abnormalities 6 (46%) 29/31 (94%) 2 (29%) 5 (25%)
Lymphocytosis 3 (WCC 11–73) 27/31 (WCC 5–200) 2 (WCC 8–20) 4 (WCC 6–25)
Oligoclonal bands 3 (23%) 5/6 (83%) 0 (0%) N/A
PCR positive 2/13 (15%) 0 (0%) 0 (0%) N/A
Immunotherapy received 11 (77%) 30/31 (97%) 4 (57%) 8 (50%)
Immunotherapy response 10/11 (90%) 22/30 (73%) 4/4 (100%) 9/12 (75%)
Ongoing problems 9/13 (69%) 20/31 (65%) 5 (71%) 12 (60%)
Patients with NMDAR encephalitis were more likely to have cognitive dysfunction and movement disorders. Seizures were seen more commonly in VGKC-complex encephalitis; these
patients were less likely to receive immunotherapy. When comparing our cohort’s clinical and paraclinical features to those in the reported literature, CSF abnormalities were seen less
frequently as were the associated malignancies (not statistically significant).
*20 paediatric patients with encephalopathy associated with VGKC-complex antibodies were reported in seven manuscripts.11–17
CSF, cerebrospinal fluid; NMDAR, N-methyl-D-aspartate receptor; WCC, white cell count.
Table 3 Comparison of the paraclinical features in paediatric
patients with antibody positive and negative encephalopathy
Antibody positive
(n=21)
Antibody negative
(n=27)
MRI abnormalities 11 (52%) 7 (26%)
Normal at presentation 14 21
Reversible changes 7 6
Atrophy 4 1
EEG abnormalities 20 (95%) 23 (88%)
Generalised encephalopathy 12 12
Focal encephalopathy 2 3
Encephalopathy with epileptic
discharges
2 2
Epileptic discharges only 3 2
Fast activity 1 1
Epileptic discharges progressing
to encephalopathy
2 5
CSF abnormalities 8 (38%) 7 (27%)
Lymphocytosis 5 (WCC 8–73) 3 (WCC 16–57)
Oligoclonal bands 3 3
MRI abnormalities were seen more commonly in the antibody negative group,
highlighted by higher rates of atrophy seen on subsequent imaging. No significant
difference was seen between the two groups.
CSF, cerebrospinal fluid; WCC, white cell count.
Table 4 Comparison of immunotherapy response and outcome in
paediatric patients with antibody positive and antibody negative
encephalopathy
Antibody positive
(n=21)
Antibody negative
(n=27)
Immunotherapy received 17 (80%) 17 (63%)
Corticosteroids only 6 11
IVIG only 0 2
Corticosteroids+IVIG 11 4
Additional PLEX 4 0
Disease modifying drugs 5 0
Immunotherapy response 16 (94%) 16 (94%)
Probable response 10 13
Definite response 6 3
Modified Rankin scale score
(for children) at nadir
4.5+0.60 4.5+0.58
Modified Rankin scale score
(for children) at follow-up
1.8+0.75 1.6+0.84
Ongoing problems (further details
in figure 3)
15 (71%) 13 (48%)
10/14 (71%) untreated 3/4 (75%) 13 (48%)
18/34 (52%) treated 12/17 (70%) 6/17 (35%)
No significant difference was seen in immunotherapy response and outcome.
Antibody positive patients were more likely to receive PLEX and second line
immunotherapy.
IVIG, intravenous immunoglobulins; PLEX, plasma exchange.
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adult5 8 25 and paediatric literature7 9 10; the existence of only
one patient with a teratoma likely reﬂects the young age of the
children studied.5 Children with VGKC-complex antibodies pre-
sented either with limbic encephalitis and prolonged seizures, or
with a less speciﬁc encephalopathy syndrome with varying
degrees of seizures and psychiatric features, as previously
reported in smaller studies.11 13 14 Only one child had an unex-
pected positive GlyR antibody which is more commonly asso-
ciated with a progressive or relapsing remitting form of stiff
person syndrome, often with additional brainstem and auto-
nomic features and mainly, but not exclusively, in adults
(Vincent A, unpublished observations).22 26 27
All recruiting centres undertook investigative studies to
exclude infective aetiologies, often with support from paediatric
infectious disease teams. Nevertheless, within the antibody posi-
tive group, 5/21 (24%) patients were positive for an acute
infective organism (HSV (2), mycoplasma (2), Epstein–Barr
virus (1)); three patients had a raised anti-streptococcal antibody
titre, and yet phenotypically they resembled NMDAR antibody
encephalitis. Indeed mycoplasma IgM positive serology has pre-
viously been reported in 50% of patients with NMDAR without
a neoplasm.28 Moreover, the two NMDAR antibody positive
patients who were also positive for HSV PCR in the CSF, con-
tinued to regress despite acyclovir treatment but improved fol-
lowing immunotherapy. It is possible that some patients have
existing antibodies that gain access to the brain when there is a
viral infection, or alternatively a para-infectious antibody-
mediated process may begin during an acute infective process.
Consistent with this, NMDAR antibodies have recently been
reported in 30% of patients with HSV encephalitis, possibly as a
secondary epiphenomenon.29
Generalised MRI atrophy was reported in 5/48 (10%) of our
patients. The small sample size did not allow us to correlate the
MRI ﬁndings with symptom severity or outcome. Postmortem
Figure 3 Outcome of all patients
with autoimmune encephalopathy.
The problems encountered in
children at follow-up of 1–5 years
(mean=24 months). Twenty patients
recovered completely. Cognitive
problems were still present in 23,
seizures in 16, behavioural problems in
17 and two patients had additional
motor problems.
Figure 4 Modiﬁed Rankin Scale
(mRS) for children score reduction in
total cohort and in the antibody
positive and negative groups, stratiﬁed
according to immunotherapies. A
signiﬁcant improvement of the mRS
score between nadir and ﬁnal
follow-up, as measured by the χ2 test,
was seen in the patients who received
immunotherapies (p=0.04) (A), with a
similar trend in the antibody positive
(B) and antibody negative (C) groups.
Hacohen Y, et al. J Neurol Neurosurg Psychiatry 2013;84:748–755. doi:10.1136/jnnp-2012-303807 753
Neuro-inﬂammation
copyright.
 o
n
 4 D
ecem
ber 2018 by guest. Protected by
http://jnnp.bmj.com/
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2012-303807 on 22 November 2012. Downloaded from 
reports of some NMDAR encephalitis patients showed pro-
nounced brain atrophy, although reversible atrophy was
observed in others who survived.30 By contrast, a recent study
of immunopathology of antibody-associated encephalopathies
including NMDAR encephalitis showed lack of neuro-axonal
injury with minimal inﬂammation in the cortex and no atrophy
on imaging.31 The cause of the atrophy in our patients, in con-
trast to the minimal changes on imaging, is unclear and could
be a result of inﬂammation, recurrent seizures or medication
(corticosteroids). Initial EEGs were encephalopathic or showed
a slow background in the majority of the patients, in keeping
with previous reports.7 9 12 Generalised seizures were most fre-
quently reported, but it is possible that focal seizures were
masked by the encephalopathic changes.
Immunosuppressive strategies with corticosteroids, IVIG and
PLEX have been used extensively in adults and are beginning to
be used more commonly in children.32 Responses to immuno-
therapy, particularly for NMDAR antibody encephalitis, can be
slow (over months) and variable, often requiring a multidiscip-
linary team for detailed management. Furthermore, the latency
to treatment is also very variable (months to years) as in
previously-reported childhood series,7 9 10 12–14 making inter-
pretation and direct comparison of treatment efﬁcacy difﬁcult.
Although complete recovery was seen in 42% of our patients, it
is important to note that learning, memory and behavioural pro-
blems were often not identiﬁed until the child was integrated
back into the educational system. NMDAR antibody associated
encephalitis can relapse in approximately 30% of adults5 8 and
25% of children,7 10 and the need for longer-term immunosup-
pression, currently maintained in only ﬁve of our patients, will
have to be considered when more data are available.
In general in our cohort, worse outcomes were seen in
patients who did not receive any immunotherapy, and delay to
therapy was likely to have inﬂuenced outcome, as seen in the
two patients who received immunotherapy late and did not
respond. Nevertheless, four patients who did not receive
immunotherapy made a complete recovery. Spontaneous recov-
eries in immune-mediated encephalopathies have been
described,12 17 33 and suggest that some of the clinical syn-
dromes may be monophasic and resolve without treatment.
Treatment decisions must balance the potential beneﬁts of early
and sustained immunotherapy in prevention of progression of
disease and in facilitating recovery.
The presence of an antibody negative group raises questions
about our selection process and the diagnosis in such patients.
First, the lag phase from clinical presentation to antibody
testing, or sampling after immunotherapy, may explain negative
tests in some of the patients. Although rare patients have anti-
bodies in CSF but not in serum,5 in this laboratory’s experience,
CSF, diluted 1:1, is never positive when the serum, diluted
1:20, is negative; indeed in the four cases with CSF available,
the serum levels were clearly higher than the CSF levels, two of
which were negative; thus lack of CSF testing is unlikely to be a
factor. Second, two of the antibody negative patients had their
serum sample taken after receiving IVIG which might have
inﬂuenced their results, but since 16/18 antibody positive
patients remained positive in the serum at 1 year from symp-
toms onset (11/12 NMDAR, 4/5 VGKC-complex and 1/1
GlyR), despite immunotherapies, it is more likely that the anti-
body negative patients have an unidentiﬁed CNS auto-antigen
or possibly some other form of immune-mediated disease.
Given that some of the antibody negative patients had move-
ment disorders, we looked for antibodies to the dopamine
receptors D1R and D2R. Antibodies to D2R have recently been
reported in a paediatric cohort with basal ganglia encephalitis.34
Those patients were phenotypically similar to a few of the anti-
body negative patients in our cohort, but we were not able to
ﬁnd any dopamine receptor antibodies in their sera.
In this systematic study of patients referred to tertiary centres,
only 44% of patients with an eventual diagnosis of probable
autoimmune encephalopathy were positive for known autoanti-
bodies. These patients were often apyrexial at presentation, had
low CSF cell counts and did not have MRI abnormalities that
were characteristic of identiﬁable viral encephalitis, features that
have helped to distinguish viral from immune aetiologies in pre-
vious studies.18 28 The similarities between patients with and
without identiﬁed antibodies indicate a need to search for new
antigenic targets that could be helpful in future diagnosis; in the
meantime diagnostic and management strategies that are often
based on antibody evaluation, and directed by one of a speciﬁc
antibody, may need to be re-evaluated.
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